<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04819568</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-Cirrhosis-39</org_study_id>
    <nct_id>NCT04819568</nct_id>
  </id_info>
  <brief_title>Comparison of Bolus Versus Continuous Infusion of Terlipressin Cirrhotic Patients With Septic Shock.</brief_title>
  <official_title>Comparison of Bolus Versus Continuous Infusion of Terlipressin Cirrhotic Patients With Septic Shock: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Septic shock is a major life-threatening vasodilatory shock. Vasopressor form a crucial&#xD;
      pharmacotherapeutic option and have long been used as the first and foremost recommended&#xD;
      therapy.(1) However, some patients may remain refractory to catecholamine, which is also&#xD;
      known as catecholamine-resistant septic shock.(2, 3) High-dose catecholamine therapy may lead&#xD;
      to potential side effects such as increased myocardial oxygen consumption, lethal arrthymias,&#xD;
      and even the high risk of mortality. (4)Therefore, newer alternatives like dopamine,&#xD;
      dobutamine, somatostatin, and terlipressin are also used.&#xD;
&#xD;
      Cirrhosis is a state of hyperdynamic circulation, which worsens with the onset of infection.&#xD;
      In septic shock, there is relative deficiency of vasopressin. (13) The mortality of septic&#xD;
      shock in these patients still remains extremely high. Terlipressin is a synthetic vasopressin&#xD;
      analogue with greater selectivity for the V1-receptors.(5) In cirrhotics with septic shock,&#xD;
      terlipressin has been used either as a continuous intravenous infusion or as intravenous&#xD;
      boluses. However, at present none of studies reveal which would be a better mode of&#xD;
      administration in cirrhotics with septic shock considering the reversal of hemodynamics and&#xD;
      safety of patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methodology:&#xD;
&#xD;
        -  Study population: All the consecutive patients of cirrhosis admitted to Intensive care&#xD;
           unit of Hepatology department of ILBS will be evaluated for inclusion&#xD;
&#xD;
        -  Study design: Prospective open label randomised controlled study -superiority trial. The&#xD;
           study will be conducted in Department of Hepatology ILBS- intensive care unit.&#xD;
&#xD;
        -  Study period: 1 year from ethics approval (Feb 21- Jan 22)&#xD;
&#xD;
        -  Sample size: Assuming that the response rate is 90% in continuous and 80% in bolus ,&#xD;
           with α=5% β=80% and the superiority margin taken as 10%; then we need to enroll 141&#xD;
           cases in each arm, further taking 10% drop out rate, we need to randomise a total of 310&#xD;
           cases (155 in each arm). Randomisation will be done by block randomisation method by&#xD;
           taking block size as 10.&#xD;
&#xD;
        -  Intervention: 250 patients after screening for all exclusion criteria randomised into 2&#xD;
           arms(group-1, Terlipressin bolus arm) and(group-2, Terlipressin continuous infusion arm)&#xD;
           in a ratio 1:1.&#xD;
&#xD;
        -  250 patients after screening for all exclusion criteria randomised into 2 arms(group-1,&#xD;
           Terlipressin bolus arm) and(group-2, Terlipressin continuous infusion arm) in a ratio&#xD;
           1:1.&#xD;
&#xD;
        -  Monitoring and assessment&#xD;
&#xD;
      Both the group will undergo assessment of cardiac function by measuring NT-Pro BNP, Troponin&#xD;
      I, ANP and baseline transthoracic echocardiography (TTE), 30 minutes after the first bolus&#xD;
      dose and after the starting of infusion, lastly at 72 hours.&#xD;
&#xD;
      TTE will be performed to evaluate the cardiac function; Cardiac output (velocity time&#xD;
      integral at aortic flow times the area of left ventricular outflow tract), LV ejection&#xD;
      fraction by modified Simpson's method, LV diastolic function by E/E' measurement, right&#xD;
      ventricular systolic function by fractional area change, tricuspid annular plane systolic&#xD;
      excursion (TAPSE), and flattening of the interventricular septum.&#xD;
&#xD;
        -  USG Doppler will be performed in all the patients to assess the flow in renal, portal,&#xD;
           hepatic veins and also permeability index, and extravascular lung volume.&#xD;
&#xD;
        -  The macro-hemodynamic parameters were MAP, heart rate, cardiac output, SVR index, global&#xD;
           end diastolic volume, extravascular lung water, lung permeability index and hourly urine&#xD;
           output. Global tissue perfusion adequacy and microcirculation assessment was done by&#xD;
&#xD;
        -  1. SVR index = MAP-CVP/CO *80 ( 700 - 1500dynes/sec/cm-5&#xD;
&#xD;
        -  2. Global EDV = combined end diastolic volume of all 4 chambers.&#xD;
&#xD;
        -  3. Lactate of Blood Gas preferably&#xD;
&#xD;
        -  4. Lactate clearance13 (defined by lactate baseline-lactate at time point/baseline&#xD;
           lactate ×100)&#xD;
&#xD;
        -  5. Central venous O2 saturation (SCV02) with a target of SCVO2&gt;70%&#xD;
&#xD;
        -  In all patients, baseline endotoxin activity assay and blood sample will be stored for&#xD;
           looking at the effect of therapy on cytokine profile (TNF alpha, IL6, IFN-gamma, and&#xD;
           ADAMTS and vWillebrand factor).&#xD;
&#xD;
        -  Improvement in Endothelial dysfunction would be assessed by measuring the biomarkers&#xD;
           such as Endotoxin, von willebrand factor and ADAMTS at three times At baseline (Hour 0),&#xD;
           at 30 minutes after Terlipressin dose and at 72 hours.&#xD;
&#xD;
        -  Renal function would be measured by serum Renin, serum cystatin C, urine NGAL,eGFR, and&#xD;
           improvement in AKI stage according to KDIGO criteria or requirement of dialysis.&#xD;
&#xD;
        -  For assessment of impact of coagulation, ROTEM would be performed at respective time.&#xD;
&#xD;
        -  Also the serum level of Noradrenaline and terlipressin will be assessed at starting and&#xD;
           after 72 hours.&#xD;
&#xD;
      STATISTICAL ANALYSIS: Continuous data- Student's t test&#xD;
&#xD;
        -  Non parametric analysis- Mann Whitney test&#xD;
&#xD;
        -  Survival outcome By Kaplan-Meier method curve.&#xD;
&#xD;
        -  For all tests, p≤ 0.05 will be considered statistically significant.&#xD;
&#xD;
        -  Analysis will be performed using SPSS .&#xD;
&#xD;
        -  The analysis will be done with intention to treat and per protocol analysis if&#xD;
           applicable.&#xD;
&#xD;
           - Adverse effects Severity of adverse events (CTACE Grade) GRADE-1&#xD;
&#xD;
        -  Loose motion(2 -3 episodes)&#xD;
&#xD;
        -  Hyponatremia (135-130) GRADE-2&#xD;
&#xD;
        -  Loose motion (4-6 episodes)&#xD;
&#xD;
        -  Abdominal pain&#xD;
&#xD;
        -  Hyponatremia (130-120) GRADE-3&#xD;
&#xD;
        -  Loose motion (&gt; 6)&#xD;
&#xD;
        -  Bacterial infections&#xD;
&#xD;
        -  Chest pain&#xD;
&#xD;
        -  Circulatory overload&#xD;
&#xD;
        -  Hponatremia( &lt;120)&#xD;
&#xD;
      GRADE-4&#xD;
&#xD;
        -  Arrhythmia&#xD;
&#xD;
        -  Myocardial Infarction&#xD;
&#xD;
        -  Mesenteric ischemia&#xD;
&#xD;
        -  Livedo reticularis&#xD;
&#xD;
        -  Respiratory acidosis&#xD;
&#xD;
        -  Hepatic encephalopathy&#xD;
&#xD;
        -  Gastrointestinal bleeding&#xD;
&#xD;
        -  Peripheral cyanosis&#xD;
&#xD;
        -  Lactic acidosis&#xD;
&#xD;
        -  Bradycardia&#xD;
&#xD;
        -  Atrial fibrillation&#xD;
&#xD;
        -  Ventricular tachycardia GRADE-5&#xD;
&#xD;
        -  Death&#xD;
&#xD;
             -  Stopping Rule: Side effects or toxicities that are severe -arrhythmia, AMI,&#xD;
                Cardiomyopathy (defined later) Cyanosis and all orther grade IV adverse effects of&#xD;
                Terlipressin.&#xD;
&#xD;
             -  Suspicion or confirmed bowel ischemia.&#xD;
&#xD;
             -  Patient unwilling for further hospital stay.&#xD;
&#xD;
             -  Study unrelated complication here the drug effects could not be assessed (massive&#xD;
                GI bleed uncontrolled, bowel perforation or any surgical intervention).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 25, 2021</start_date>
  <completion_date type="Anticipated">March 19, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 19, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reversal of shock</measure>
    <time_frame>72 hours</time_frame>
    <description>DISCONTINUATION OF NOREPINEPHRINE IS CONSIDERED AS REVERSAL OF SHOCK.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to reversal of shock</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse effects and discontinuation of therapy due to adverse effects</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse effects and discontinuation of therapy due to adverse effects</measure>
    <time_frame>Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on AKI (Progression, Resolution, requirement of renal replacement therapy, (RRT)</measure>
    <time_frame>24 hours</time_frame>
    <description>AS PER KDIGO STAZE, AKI HAS BEEN DEFINED. INCREMENT OF ONE OR MORE STAZE OR REQUIREMENT OF RRT IS CONSIDERED AS PROGRESSION.&#xD;
REMAINING SAME STAZE IS CONSIDERED AS PERSISTENT. DECREMENT OF ONE OR MORE STAZE IS CONSIDERED AS IMPROVEMENT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on AKI (Progression, Resolution, requirement of renal replacement therapy, (RRT)</measure>
    <time_frame>Day 3</time_frame>
    <description>AS PER KDIGO STAZE, AKI HAS BEEN DEFINED. INCREMENT OF ONE OR MORE STAZE OR REQUIREMENT OF RRT IS CONSIDERED AS PROGRESSION.&#xD;
REMAINING SAME STAZE IS CONSIDERED AS PERSISTENT. DECREMENT OF ONE OR MORE STAZE IS CONSIDERED AS IMPROVEMENT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on AKI (Progression, Resolution, requirement of renal replacement therapy, (RRT)</measure>
    <time_frame>Day 7</time_frame>
    <description>AS PER KDIGO STAZE, AKI HAS BEEN DEFINED. INCREMENT OF ONE OR MORE STAZE OR REQUIREMENT OF RRT IS CONSIDERED AS PROGRESSION.&#xD;
REMAINING SAME STAZE IS CONSIDERED AS PERSISTENT. DECREMENT OF ONE OR MORE STAZE IS CONSIDERED AS IMPROVEMENT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in SOFA score</measure>
    <time_frame>24 hours</time_frame>
    <description>IMPROVEMENT BY ATLEAST 2 POINTS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in SOFA score</measure>
    <time_frame>Day 3</time_frame>
    <description>IMPROVEMENT BY ATLEAST 2 POINTS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lactate clearance</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lactate clearance</measure>
    <time_frame>12 hours</time_frame>
    <description>DECREMENT OF 25% LACATATE DELTA LACTATE = CURRENT LACTATE/BASELINE LACTATE *100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lactate clearance</measure>
    <time_frame>24 hous</time_frame>
    <description>DECREMENT OF 25% LACATATE DELTA LACTATE = CURRENT LACTATE/BASELINE LACTATE *100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lactate clearance</measure>
    <time_frame>72 hours</time_frame>
    <description>DECREMENT OF 25% LACATATE DELTA LACTATE = CURRENT LACTATE/BASELINE LACTATE *100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of mechanical ventilation</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of Intensive Care Unit stay</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Terlipressin Bolus Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Terlipressin Continuous Infusion Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terlipressin</intervention_name>
    <description>Terlipressin Bolus Max dose 2 mg/24 hr.i.e 0.5 mg qid</description>
    <arm_group_label>Terlipressin Bolus Arm</arm_group_label>
    <arm_group_label>Terlipressin Continuous Infusion Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Standard of Care</description>
    <arm_group_label>Terlipressin Bolus Arm</arm_group_label>
    <arm_group_label>Terlipressin Continuous Infusion Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Cirrhotics including ACLF with septic shock requiring norepinephrine dose &gt;0.5ug/kg/min&#xD;
        to maintain MAP&gt; 65 mm Hg&#xD;
&#xD;
        - An informed consent from the patient or relative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with age less than 18 years or more than 65 years&#xD;
&#xD;
          -  Severe known cardiopulmonary disease (Hypertension, structural or valvular heart&#xD;
             disease, coronary artery disease, arrhythmias)&#xD;
&#xD;
          -  Stroke&#xD;
&#xD;
          -  Peripheral Vascular disease&#xD;
&#xD;
          -  Gut Paralysis&#xD;
&#xD;
          -  Intestinal obstruction&#xD;
&#xD;
          -  Cancer, hepato-cellular carcinoma (HCC), intrahepatic or extrahepatic malignancy&#xD;
&#xD;
          -  Portal vein thrombosis&#xD;
&#xD;
          -  Hepatic vein outflow tract obstruction (HVOTO )&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Patients with Pa02/FiO2 ratio &lt;150&#xD;
&#xD;
          -  Severe coagulopathy platelets &lt;20,000 and INR &gt; 4&#xD;
&#xD;
          -  Active Bleed (Mucosal or variceal)&#xD;
&#xD;
          -  Patients already on terlipressin in the last 48 hours&#xD;
&#xD;
          -  Extremely moribund patients with an expected life expectancy of less than 24 hours&#xD;
&#xD;
          -  Failure to give informed consent from family members.&#xD;
&#xD;
          -  Patient enrolled in other clinical trials&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr Priti Gupta, MD</last_name>
    <phone>01146300000</phone>
    <email>priti7vns@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Liver &amp; Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Priti Gupta, MD</last_name>
      <phone>01146300000</phone>
      <email>priti7vns@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 15, 2021</study_first_submitted>
  <study_first_submitted_qc>March 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terlipressin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

